SARS-CoV-2 and Influenza Coinfection Among Persons Tested in US Pharmacies - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Concurrent SARS-CoV-2 and Influenza Infections Among People Tested at US Pharmacies

  • By

  • Pragna Patel

  • Jessica K. Sprinkles

  • Andrew Godoshian

  • Marcus Siddall

  • Timothy M. Uyeki

  • Henry Walke

  • Joseph Miller

  • November 18, 2026

Share

  • 1

    In this nationwide pharmacy cohort of 817,834 people tested from September 2023 through May 2025, 665 tested positive for both SARS-CoV-2 and influenza.

  • 2

    Overall coinfection prevalence was 0.081% (95% CI, 0.075%-0.087%) and was highest among children younger than 18 years at 0.145%.

  • 3

    Compared with adults aged 18 to 64 years, children had higher adjusted odds of coinfection (OR, 1.93; 95% CI, 1.42-2.57), while adults aged 65 years or older had lower odds (OR, 0.69; 95% CI, 0.53-0.8

  • 4

    Among 665 people with coinfection, 26 (3.9%) received COVID-19 treatment and 29 (4.4%) received influenza treatment; none received treatment for both infections.

  • 5

    The authors reported that survey-related bias, nonresponse, prescriptions received elsewhere, and lack of adjustment for pharmacy clustering limited the available data and generalizability.

Original Source(s)

Related Content